ATE301201T1 - Für die gentherapie verwendbare plasmide - Google Patents

Für die gentherapie verwendbare plasmide

Info

Publication number
ATE301201T1
ATE301201T1 AT94919290T AT94919290T ATE301201T1 AT E301201 T1 ATE301201 T1 AT E301201T1 AT 94919290 T AT94919290 T AT 94919290T AT 94919290 T AT94919290 T AT 94919290T AT E301201 T1 ATE301201 T1 AT E301201T1
Authority
AT
Austria
Prior art keywords
pct
gene therapy
date dec
sec
plasmids usable
Prior art date
Application number
AT94919290T
Other languages
English (en)
Inventor
Gary J Nabel
Elizabeth G Nabel
Denise Lew
Magda Marquet
Original Assignee
Vical Inc
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc, Univ Michigan filed Critical Vical Inc
Application granted granted Critical
Publication of ATE301201T1 publication Critical patent/ATE301201T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/55IL-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/42Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/44Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
AT94919290T 1993-06-07 1994-05-27 Für die gentherapie verwendbare plasmide ATE301201T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7434493A 1993-06-07 1993-06-07
PCT/US1994/006069 WO1994029469A2 (en) 1993-06-07 1994-05-27 Plasmids suitable for gene therapy

Publications (1)

Publication Number Publication Date
ATE301201T1 true ATE301201T1 (de) 2005-08-15

Family

ID=22119050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94919290T ATE301201T1 (de) 1993-06-07 1994-05-27 Für die gentherapie verwendbare plasmide

Country Status (7)

Country Link
US (1) US5910488A (de)
EP (1) EP0702722B1 (de)
JP (1) JP3626187B2 (de)
AT (1) ATE301201T1 (de)
CA (1) CA2164088C (de)
DE (1) DE69434447T2 (de)
WO (1) WO1994029469A2 (de)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US6936464B1 (en) 1992-10-02 2005-08-30 Cancer Research Technology Limited Immune responses to fusion proteins
WO1996006938A1 (de) * 1994-08-26 1996-03-07 Hoechst Aktiengesellschaft Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
DE69636068T2 (de) * 1995-02-21 2006-11-30 Cantab Pharmaceuticals Research Ltd. Virale zubereitungen, vektoren, immunogene und impfstoffe
WO1996034112A1 (en) * 1995-04-24 1996-10-31 Chromaxome Corp. Methods for generating and screening novel metabolic pathways
US6265387B1 (en) * 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US7507722B1 (en) * 1999-11-05 2009-03-24 Roche Madison Inc. Intravascular delivery of nucleic acid
US6153380A (en) 1996-01-23 2000-11-28 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US5783431A (en) * 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
US6242211B1 (en) 1996-04-24 2001-06-05 Terragen Discovery, Inc. Methods for generating and screening novel metabolic pathways
EP0803573A1 (de) * 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronische Expressionskonstrukt mit Cytokinen für multivalente Impstoffe
EP0805207A1 (de) * 1996-05-02 1997-11-05 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronische Expressionsplasmid für Tumorabstossungen
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
AU6260098A (en) * 1997-02-24 1998-09-09 Hoechst Marion Roussel, Inc. Improved assays for beta-amyloid processing
WO1999017798A1 (en) 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
CA2309766C (en) * 1997-11-20 2008-09-30 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US9585916B2 (en) 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
CA2266805C (en) 1998-03-27 2015-04-28 An-Go-Gen Inc. Cell-based gene therapy in the treatment of pulmonary disorders
US6482406B1 (en) 1999-03-26 2002-11-19 Duncan J. Stewart Cell-based gene therapy for the pulmonary system
US6592623B1 (en) 1999-08-31 2003-07-15 Virginia Commonwealth University Intellectual Property Foundation Engineered muscle
EP1955709B1 (de) 1999-03-26 2012-03-14 Vical Incorporated Adjuvanzverbindungen zur Verbesserung von Immunreaktionen auf Polynukleotid-basierten Impfstoffen
WO2000061184A2 (en) * 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6541458B1 (en) * 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
WO2001032223A1 (en) * 1999-11-05 2001-05-10 Mirus Corporation Intravascular delivery of nucleic acid
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
US20010049144A1 (en) * 1999-12-10 2001-12-06 Victor Rivera Methods for high level expression of genes in primates
US7078388B2 (en) * 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
EP1278551A2 (de) * 2000-04-21 2003-01-29 Vical Incorporated Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika
US6645745B1 (en) 2000-05-30 2003-11-11 Epidauros Biotechnologie Ag Identification of a new member of the cytochrome P450 3A (CYP3A) gene family: CYP3AX
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
CA2420325A1 (en) 2000-08-25 2002-02-28 Basf Plant Science Gmbh Plant polynucleotides encoding novel prenyl proteases
AU2001287023A1 (en) 2000-09-01 2002-03-13 Virginia Commonwealth University Intellectual Property Foundation Plasma-derived-fibrin-based matrices and tissue
JP2005500806A (ja) 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー CpGに基づく免疫アゴニスト/免疫アンタゴニストの高スループットスクリーニングのためのプロセス
US20030074679A1 (en) * 2000-12-12 2003-04-17 Schwartz Robert J. Administration of nucleic acid sequence to female animal to enhance growth in offspring
WO2002059142A2 (en) 2001-01-26 2002-08-01 Epidauros Biotechnologies Ag Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications
PT1372708E (pt) 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
AU2002326751A1 (en) * 2001-08-13 2003-03-03 Ige Therapeutics, Inc. Immunoglobulin e vaccines and methods of use thereof
US20080206202A1 (en) * 2001-09-24 2008-08-28 Christopher Reid Methods for application of endogenous or exogenous stem/progenitor or their progeny for treatment of disease
US20030109037A1 (en) * 2001-09-24 2003-06-12 Reid Christopher Brian Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DK1355152T3 (da) 2002-04-17 2010-06-14 Deutsches Krebsforsch Fremgangsmåde til at identificere en forbindelse til modulering af wnt-signalkaskaden
US20060093589A1 (en) * 2004-02-19 2006-05-04 Warrington Kenneth H Vp2-modified raav vector compositions and uses therefor
US8802080B2 (en) * 2002-05-01 2014-08-12 University Of Florida Research Foundation, Inc. Raav expression systems for genetic modification of specific capsid proteins
US7771952B2 (en) 2002-06-26 2010-08-10 Abott Laboratories Modulators and modulation of the interaction between RGM and Neogenin
US6809191B2 (en) * 2002-07-03 2004-10-26 Vaxim, Inc. GM-CSF nucleic acid sequences
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2003302724A1 (en) * 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
US7595192B2 (en) 2002-08-16 2009-09-29 Glycotype Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
JP2006516182A (ja) 2002-08-23 2006-06-29 エピダウロス ビオテヒノロギー アーゲー Oct1のヒト遺伝子における多型、ならびに診断および治療用途におけるその使用
US20070225631A1 (en) * 2002-10-04 2007-09-27 Bowlin Gary L Sealants for Skin and Other Tissues
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040136960A1 (en) * 2003-01-10 2004-07-15 Wolff Jon A. Devices and processes for distribution of genetic material to mammalian limb
SG190613A1 (en) 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
EP1654353B1 (de) 2003-08-18 2013-05-22 Glycotope GmbH Tumor-zellinien nm-f9 (dsm acc2606) und nm-d4 (dsm acc2605), deren verwendungen
EP2093298A3 (de) 2003-10-10 2009-09-23 Deutsches Krebsforschungszentrum Zusammensetzungen zur Diagnose und Therapie für mit aberranter Expression von Futrins (R-Spondins) assoziierten Krankheiten
ZA200601699B (en) 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
ES2484340T3 (es) 2003-12-05 2014-08-11 Multimmune Gmbh Anticuerpos anti hsp70 terapéuticos y diagnósticos
NZ548926A (en) 2004-02-09 2009-07-31 Regenion Gmbh Inhibitors of TGF-R signaling for treatment of CNS disorders
US7504243B2 (en) 2004-03-19 2009-03-17 The United States Of America As Represented By The Department Of Health And Human Services Methods for the production of biliverdin
US8492106B2 (en) 2004-05-24 2013-07-23 Universitat Zu Koln Identification methods for ergothioneine transporter modulators and therapeutic uses thereof
EP1602926A1 (de) 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
CN101094688B (zh) 2004-09-13 2013-05-01 建新公司 多聚构建体
WO2006032436A2 (en) 2004-09-21 2006-03-30 Nascacell Technologies Ag. Use of microproteins as tryptase inhibitors
EP1877087B1 (de) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren und zusammensetzungen zur erzeugung einer verbesserten immunantwort auf ein menschliches papillomavirus-immunogen
US8048446B2 (en) * 2005-05-10 2011-11-01 Drexel University Electrospun blends of natural and synthetic polymer fibers as tissue engineering scaffolds
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US20090068158A1 (en) * 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
US20090074733A1 (en) * 2005-12-09 2009-03-19 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
PT1976880T (pt) 2005-12-21 2016-09-28 Amgen Res Munich Gmbh Composições farmacêuticas com resistência a cea solúvel
DK2514823T3 (en) 2006-03-03 2018-07-23 Promis Neurosciences Inc Methods and compositions for treating and detecting failed SOD1-mediated diseases
CA2655990A1 (en) 2006-06-22 2007-12-27 Tai June Yoo Restoration of hearing loss
PT2073842E (pt) 2006-09-10 2015-04-07 Glycotope Gmbh Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos
EP1920782A1 (de) 2006-11-10 2008-05-14 Glycotope Gmbh Mikroorganismen oder deren Fraktionen fähig zur Aktivierung von Zelleimmunität gegen Kohlenhydrate
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
CA2673331A1 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
AU2007344641B2 (en) 2007-01-16 2014-05-22 The University Of Queensland Method of inducing an immune response
CA2677273A1 (en) 2007-02-06 2008-08-14 Tai-June Yoo Use of a composition comprising a cytokine encoding nucleic acid for treating alzheimer's disease
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
CN109456410B (zh) 2007-04-03 2022-01-28 安进研发(慕尼黑)股份有限公司 跨物种特异性CD3-ε结合结构域
SG10201808730VA (en) 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
WO2008124768A1 (en) 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
AU2007352618B2 (en) 2007-05-02 2013-07-18 Boehringer Ingelheim Animal Health USA Inc. DNA plasmids having improved expression and stability
JP2010526528A (ja) 2007-05-03 2010-08-05 メディツィニーチェ ウニベルシタット インスブルック 補体因子h由来ショートコンセンサスリピート−抗体構築物
EP3293266B1 (de) 2007-05-04 2025-12-24 University Health Network Il-12-immuntherapie gegen krebs
CA2688346A1 (en) 2007-05-23 2008-12-04 Vical Incorporated Compositions and methods for enhancing immune responses to vaccines
PT2164993T (pt) 2007-05-29 2017-01-12 Reid Christopher B Métodos para produção e usos de populações de células multipotentes, populações de células pluripotentes, populações de célula diferenciadas e populações de células resistentes a vih
EP2246432A2 (de) 2008-01-29 2010-11-03 Proyecto de Biomedicina Cima, S.L. Verfahren und zusammensetzungen mit der fähigkeit zur synergistischen herbeiführung von posttranskriptionalem silencing der genexpression
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US8568709B2 (en) 2008-03-20 2013-10-29 University Health Network Thymidylate kinase fusions and uses thereof
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
US9694055B2 (en) 2008-05-09 2017-07-04 Wake Forest University Health Sciences Renal tissue regeneration
EP4180458A1 (de) 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Bispezifischer einkettiger psma x cd3-antikörper mit artenübergreifender spezifität
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
US8470792B2 (en) 2008-12-04 2013-06-25 Opko Pharmaceuticals, Llc. Compositions and methods for selective inhibition of VEGF
AU2010226434A1 (en) 2009-03-20 2011-10-13 Egen, Inc. Polyamine derivatives
US8748581B2 (en) 2009-04-10 2014-06-10 Ablynx N.V. Anti-IL-6R polypeptides and pharmaceutical compositions thereof
KR101852204B1 (ko) 2009-06-05 2018-04-26 아블린쓰 엔.브이. 기도 감염의 예방 및/또는 치료를 위한 일가, 이가 및 삼가 항 인간 호흡기 세포융합 바이러스 (hrsv) 나노바디 구조물
BR112012002628B1 (pt) * 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
US8993741B2 (en) 2009-11-17 2015-03-31 The Trustees Of The University Of Pennsylvania SMNdelta7 degron: novel compositions and methods of use
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 rgm a 단백질에 대한 모노클로날 항체
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究(慕尼黑)有限責任公司 跨物種專一性之PSMAxCD3雙專一性單鏈抗體
ES2657705T3 (es) 2010-06-23 2018-03-06 Deutsches Krebsforschungszentrum Secuencias de virus TT específicas y moléculas de ADN quiméricas de células hospedadoras de virus TT para uso en el diagnóstico, prevención y tratamiento del cáncer y la autoinmunidad
WO2011160848A1 (en) 2010-06-23 2011-12-29 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechtes Rearranged tt virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
EP2481801A1 (de) 2011-01-28 2012-08-01 Deutsches Krebsforschungszentrum Inhibitoren von verzweigtkettiger Aminotransferase-1 (BCAT1) zur Behandlung von Neoplasie
US8951736B2 (en) 2011-04-29 2015-02-10 Sequenom, Inc. Multimer glycosylated nucleic acid binding protein conjugates and uses thereof
EP2532747B1 (de) 2011-06-09 2015-12-02 Deutsches Krebsforschungszentrum Modulatoren von Glycerin-3-phosphatdehydrogenase (GPD2) zur Therapie
US20140120106A1 (en) 2011-07-06 2014-05-01 Yale University Stimulation of Arterial Collateral Growth and Lymphogenesis
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
JP6148671B2 (ja) 2011-08-22 2017-06-14 グリコトープ ゲーエムベーハー 腫瘍抗原を保有する微生物
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
EP3369746A1 (de) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Zusammensetzung und verfahren zur diagnose und behandlung von krankheiten im zusammenhang mit neuritenabbau
MX366965B (es) 2012-02-03 2019-07-31 Hoffmann La Roche Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
EP2657340B1 (de) 2012-04-25 2016-11-16 Deutsches Krebsforschungszentrum Hemmer von mit Thioredoxin interagierendem Protein (TXNIP) zur Therapie
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
AU2013344375B2 (en) 2012-11-16 2017-09-14 Transposagen Biopharmaceuticals, Inc. Site-specific enzymes and methods of use
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
AU2014320262B2 (en) 2013-09-16 2019-06-13 Cemm - Forschungszentrum Fur Molekulare Medizin Gmbh Mutant calreticulin for the diagnosis of myeloid malignancies
KR102319843B1 (ko) 2013-09-25 2021-10-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
EP2868751A1 (de) 2013-10-30 2015-05-06 Deutsches Krebsforschungszentrum HCBI-Sequenzen als früher Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des zentralen Nervensystems, und als Ziel zur Behandlung und Prävention von Krebs
EP2937096B1 (de) 2014-04-23 2019-08-21 Julius-Maximilians-Universität Würzburg Aus RS1 abgeleitete Peptide, die Glukoseabsorption nach einer glukosereichen Mahlzeit herunterregulieren und die Insulinsensitivität steigern
US20170073690A1 (en) 2014-05-15 2017-03-16 CEMM - Forschungzentrum Fuer Molekulare Medizin GMBH Antagonists of slc38a9 and their use in therapy
EP2966176A1 (de) 2014-07-10 2016-01-13 Deutsches Krebsforschungszentrum HCBIO-, MSBI-, MSSI- und CMI-Sequenzen als frühe Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des ZNS und als Ziel zur Behandlung und Prävention dieser Erkrankungen
JP6959869B2 (ja) 2015-02-23 2021-11-05 シーガル セラピューティクス エスアーエス 非天然セマフォリン3およびそれらの医学的使用
ES2886599T3 (es) 2015-06-17 2021-12-20 Poseida Therapeutics Inc Composiciones y métodos para dirigir proteínas a loci específicos en el genoma
CN112933094B (zh) 2015-06-18 2024-07-26 听治疗有限责任公司 预防和治疗听力损失的方法和组合物
PL3394266T3 (pl) 2015-12-22 2021-12-13 Xl-Protein Gmbh Kwasy nukleinowe kodujące powtarzalne sekwencje aminokwasowe bogate w reszty proliny i alaniny, które mają sekwencje nukleotydowe o niskiej powtarzalności
EP3216458A1 (de) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
US10036024B2 (en) 2016-06-03 2018-07-31 Purdue Research Foundation siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
AU2017291262A1 (en) 2016-06-30 2019-01-03 F. Hoffmann-La Roche Ag Improved adoptive T-cell therapy
BR112019017629A2 (pt) 2017-03-27 2020-04-07 Hoffmann La Roche receptor de união ao antígeno, polinucleotídeo isolado, vetor, célula t transduzida, métodos para o tratamento de uma doença e para induzir a lise, utilização do receptor e receptor
IL269531B2 (en) 2017-03-27 2024-10-01 Hoffmann La Roche Improved antigen binding receptors
US11590202B2 (en) 2017-04-11 2023-02-28 University Of Maryland, Baltimore Inhibitors of LTβR-NFκB signaling pathways for treating inflammation and cancer
WO2019126578A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
WO2019207051A1 (en) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Medical use of combinations of non-natural semaphorins 3 and antimetabolites
HRP20240756T1 (hr) 2018-05-18 2024-09-13 Daiichi Sankyo Co., Ltd. Anti-muc1-eksatekan antitijelo-lijek konjugat
EP3686289A1 (de) 2019-01-24 2020-07-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Cmi-sequenzen als frühmarker für die zukünftige entwicklung von krebs, atherosklerose, diabetes und erkrankungen des zns und als ziel für die behandlung und prävention dieser erkrankungen
WO2022029051A1 (en) 2020-08-03 2022-02-10 F. Hoffmann-La Roche Ag Improved antigen binding receptors
AR124562A1 (es) 2020-10-28 2023-04-12 Hoffmann La Roche Receptores de unión al antígeno mejorada
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
WO2022157548A1 (en) 2021-01-24 2022-07-28 Forrest Michael David Inhibitors of atp synthase - cosmetic and therapeutic uses
EP4373859A1 (de) 2021-07-22 2024-05-29 F. Hoffmann-La Roche AG Heterodimere fc-domänen-antikörper
KR20240111753A (ko) 2021-11-25 2024-07-17 에프. 호프만-라 로슈 아게 개선된 항원 결합 수용체
CN119095881A (zh) 2022-03-25 2024-12-06 豪夫迈·罗氏有限公司 经改善的嵌合受体
AR129560A1 (es) 2022-06-08 2024-09-04 Tidal Therapeutics Inc Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
KR20250033248A (ko) 2022-08-09 2025-03-07 후난 런스타 바이오테크 씨오., 엘티디. 금속-인지질 복합체, 금속-인지질 복합체 입자 및 약물-지질 입자 및 이의 제조 방법과 응용
EP4606388A1 (de) 2022-08-09 2025-08-27 Hunan Lonstar Biotech Co., Ltd. Metall-polyphenol-komplexpartikel, wirkstoff-lipid-partikel, verfahren zur herstellung davon und verwendung davon
TWI872406B (zh) * 2022-12-07 2025-02-11 日商都滾筒工業股份有限公司 有孔搬送輥、片材製造裝置及片材加工裝置
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
WO2026072557A2 (en) 2024-09-24 2026-04-02 Genzyme Corporation Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69233725T2 (de) * 1991-06-28 2009-02-12 The Regents Of The University Of Michigan, Ann Arbor Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren

Also Published As

Publication number Publication date
CA2164088C (en) 2005-06-14
WO1994029469A2 (en) 1994-12-22
DE69434447D1 (de) 2005-09-08
DE69434447T2 (de) 2006-05-18
US5910488A (en) 1999-06-08
CA2164088A1 (en) 1994-12-22
WO1994029469A3 (en) 1995-03-23
JP3626187B2 (ja) 2005-03-02
JPH08510911A (ja) 1996-11-19
EP0702722A1 (de) 1996-03-27
EP0702722B1 (de) 2005-08-03

Similar Documents

Publication Publication Date Title
DE69434447D1 (de) Für die gentherapie verwendbare plasmide
AU6787894A (en) Adenoviral vectors of animal origin and use in gene therapy
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
DE69434808D1 (de) Adenoviren mit veränderten faserproteinen
ATE319827T1 (de) Polypeptid, das die differenzierung unterdrueckt
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
HUT73215A (en) Recombinant adenoviruses and use thereof in gene therapy
EP0744408A3 (de) Das ob Protein der Rhesusaffen und seine DNA
HU9401604D0 (en) Production of proteins using fb2 protein
AP2000001999A0 (en) Gene therapy method.
AU5810498A (en) Method and constructs for inhibiting protein expression in bacteria
ATE226094T1 (de) Verfahren zur arzneistoffabgabe mittels gentherapie
MXPA05004973A (es) Agentes para aliviar el dolor.
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
GB2249312B (en) Cell growth inhibitors
AU4037299A (en) Genetically-modified fibroblasts and the use thereof
CA2139430A1 (fr) Polypeptides ayant une activite de recepteur serotoninergique (5ht5a), acides nucleiques codant pour ces polypeptides et utilisations
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
WO1995006744A3 (en) Methods of suppressing immune response by gene therapy
DE69434072D1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
GB2333527A (en) Therapeutic gene
NZ336371A (en) Human gene therapy using DNA/RNA cassette expression systems
CA2278223A1 (fr) Derives de la 1,4-dihydropyridine et leur utilisation en therapeutique

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties